Feature | SCAI | May 01, 2017

Late-Breaking Clinical Trial Presentations at SCAI 2017

a list of SCAI late breaking trial presentations

May 30, 2017 — The Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions took place May 10-13, 2017 in New Orleans. The annual meeting included several late-breaking presentations on the latest advances in interventional cardiology. Article links are included for the key presentations.

 

Late-breaking Study Presentations

Adventitial Dexamethasone Reduces Inflammatory Biomarker Levels After Peripheral Artery Balloon Angioplasty or Atherectomy: Results from the DANCE Trial. Presented by Ehrin J. Armstrong, M.D., MSc, MAS, FSCAI.

CD34+ Stem Cell Therapy Improves Exercise Time and Mortality in Refractory Angina: A Patient Level Meta-Analysis. Presented by Thomas J. Povsic, M.D., Ph.D.

Effect of Bivalirudin Versus Unfractionated Heparin in Patients with Baseline or New-Onset Atrial Fibrillation in Transcatheter Aortic Valve Replacement: From the BRAVO-3 Randomized Trial. Presented by Anita W. Asgar

Clopidogrel Response Evaluation and Anti-Platelet Intervention in High Thrombotic Risk PCI Patients (CREATIVE trial). Presented by Yida Tang, M.D., Ph.D., FSCAI.

Impact of Valve Design and Bivalirudin vs. Unfractionated Heparin for Anticoagulation in Transcatheter Aortic Valve Replacement: Results from the BRAVO-3 trial. Presented by Axel Linke, M.D.

Interaction Effects of Race/Ethnicity and Sex on Outcomes after PCI: A Subanalysis of the PLATINUM Diversity study. Presented by Wayne B. Batchelor, M.D., MHS, FSCAI.

Outcomes of Early vs. Late Revascularization in Low and High Risk Patients Hospitalized with Non ST-Elevation Myocardial Infarction: The Atherosclerosis Risk in Communities (ARIC) Surveillance Study. Presented by Sameer Arora, M.D., at 11:30 a.m. 

Efficacy and Safety Outcomes of Radial vs. Femoral-Access Robotic Percutaneous Coronary Intervention: Final Results of the Multicenter PRECISION Registry. Presented by Ehtisham Mahmud, M.D., FSCAI.

• Day of the Week PCI-Related Hospitalization Occurs Determines Likelihood of Survival. Presented by Byomesh Tripathi, M.D.

 

SCAI Video Coverage

Watch VIDEO coverage of key SCAI 2017 news, courses and trials at www.youtube.com/playlist?list=PLYpLxw1Ganwa5kJFa3TrFAY5l1-Jeu9Ax

 

Late-breaking Trials From TCT and ACC: 

ACC 2017 Late-Breaking Trials

TCT 2016 Late-breaking Trials and First Reports

 

For more information: www.scai.org/SCAI2017/default.aspx

Related Content

News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Overlay Init